Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
Date:1/11/2011

NOVATO, Calif., Jan. 11, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development for the treatment of genetically-defined cancers.  

"PARP inihibtors have been validated to show survival benefits in cancer patients with tumors that have defects in DNA repair or in combination with DNA damaging agents, and BMN 673 appears to have superior potency, selectivity, and bioavailability as compared to other products in development," said Hank Fuchs, Chief Medical Officer of BioMarin.  "There are many possible targets for PARP inhibitors, and we hope to identify which cancers are more susceptible to treatment with BMN 673 in the Phase 1/2 trial.  We remain intently focused on developing our R&D pipeline and look forward to many clinical milestones in the coming year."

The Phase 1/2 trial is an open-label study of once daily, orally administered BMN 673 in approximately 70 patients ages 18 and older with advanced or recurrent solid tumors.  The primary objective of the study is to establish the maximum tolerated dose of daily oral BMN 673.  The secondary objectives are to assess the safety, tolerability, preliminary efficacy and phatrmacodynamic activity of BMN 673, and to determine the pharmacokinetic profile and recommended Phase 2 dose.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a produ
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
2. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
3. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
4. BioMarin Announces Third Quarter 2010 Financial Results
5. BioMarin to Host a Research and Development Day on October 19th
6. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
9. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
10. BioMarin Acquires ZyStor Therapeutics, Inc.
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Decision Resources Group finds that ... Memphis health system and hospital sector ... with rivals Methodist Le Bonheur Healthcare and Baptist Memorial ... coordinate patient care. In addition, a national contract recently ... health plan enrollment in the Memphis ...
(Date:8/27/2014)... ALBANY, New York , August 27, 2014 /PRNewswire/ ... on United States  Laparoscopes Market Outlook ... to 2020", provides key market data on the ... in millions of US dollars, volume (in units) and ... Laparoscopes (Rigid Tip Video Laparoscopes and Flexible Tip Video ...
(Date:8/27/2014)... 27, 2014 An experimental drug designed to help ... first treatment for anemia of inflammation, according to results from ... online today in Blood , the Journal ... Anemia is a condition that occurs when red ... properly. When an individual has anemia, the body does not ...
Breaking Medicine Technology:Memphis-area Health Systems Turn Attention to Clinical Integration 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3
... & Melinda Gates Foundation today announced that Dr. Trevor Mundel ... Mundel, who is currently global head of development for Novartis ... work at the foundation on December 1. "We ... our global health program," said Bill Gates, co-chair of the ...
... Inc. is pleased to announce its exclusive agreement with ... automated FIT product, a fecal occult blood analyzer that ... the early detection of colorectal cancer. The agreement includes ... and OC-Sensor Diana, a high throughput automated FIT analyzer, ...
Cached Medicine Technology:Gates Foundation Names Dr. Trevor Mundel to Lead Global Health Program 2Polymedco, Inc., and Cardinal Health Sign Agreement for Distribution of Oncologic Diagnostic Test Kits to Acute Care Market 2
(Date:8/27/2014)... of the last things a parent wants to deal ... less than a week old. , Skin that turns ... is jaundiced and isn,t adequately eliminating the chemical bilirubin. ... severe jaundice left untreated can harm a baby. , ... smartphone application that checks for jaundice in newborns and ...
(Date:8/27/2014)... symptoms, did you look for advice online before ... alone. Consumers are increasingly turning to forums, video-sharing ... information and advice, which may distract them from ... be presented at the HFES 2014 Annual Meeting ... use the Internet to collect health-care information. ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 For nearly ... performances by the beloved mantra singers Deva Premal & ... Following the release of their latest album in May, ... down in twenty-two countries around the globe, including Russia, ... Argentina and across Europe. With a new album and ...
(Date:8/27/2014)... BESLER Consulting , a leading ... hospitals, is pleased to announce that it has been ... Fastest-Growing Companies. The list represents the most comprehensive look ... , "It's been an exciting year for our ... this year's Inc. 5000 list,” said Jonathan Besler, BESLER’s ...
(Date:8/27/2014)... 27, 2014 Home Care Assistance ... for seniors, is proud to announce the next installment ... webinar will feature Dr. Suzanne Steinbaum, attending cardiologist and ... in New York City, National Spokesperson for the American ... will cover the issues surrounding women and heart disease, ...
Breaking Medicine News(10 mins):Health News:New smartphone app can detect newborn jaundice in minutes 2Health News:New smartphone app can detect newborn jaundice in minutes 3Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3
... WASHINGTON, Oct. 21 A report,( http://www.firstfocus.net/pages/3519/ ... in the health care plans of the presidential,candidates, ... identifies,both opportunities and concerns with the policy changes ... whether the plans would ensure,access to comprehensive and ...
... today a new agreement with Sun Healthcare Group to offer public ... Healthcare Corporation, collectively operate 208 skilled nursing, long-term care and assisted ... operating beds as of June 2008. , ... ...
... Oct. 21 In a ceremony today at,the Air ... Health with a model of an S-76(R) helicopter in,recognition ... helicopters. Sikorsky is a subsidiary of United Technologies Corp.,(NYSE: ... its new S-76C++(TM) helicopter earlier,this year and is exhibiting ...
... addicted to ... opioid painkillers and heroin., FARMINGTON, Conn., Oct. 21 Launched ... has connected nearly 14,000 addicted patients with physicians,certified to prescribe Suboxone ... allowed by law to prescribe this,treatment, and those that do have ...
... School Vikings score the title of Body By Milk ... and staying fit has,become second nature to the superstar ... "got milk?(R)" campaign announced today that the,Tigers Varsity football ... MVP,(Milk,s Valued Players). The team was nominated to be ...
... 21 Isolagen(TM), Inc. (Amex:,ILE) announced today that ... Study IT-A-008 investigating Isolagen Therapy(TM) for the treatment,of ... half of all,of the study participants have completed ... will conclude in the first quarter of,2009., ...
Cached Medicine News:Health News:New Report Analyzes How Children Fare in Candidates' Health Care Plans 2Health News:New Report Analyzes How Children Fare in Candidates' Health Care Plans 3Health News: Wayport Signs Agreement with Sun Healthcare Group to Enable Public Internet Access : Sun's Inpatient Services Subsidiaries to Utilize Public Applications Managed by Wayport 2Health News:Sikorsky Aircraft Recognizes Aero Med Spectrum Health Hospitals 2Health News:NAABT Patient/Physician Matching System A Success 2Health News:NAABT Patient/Physician Matching System A Success 3Health News:North Carolina School Wins National got milk?(R) Refuel Your School Contest 2Health News:North Carolina School Wins National got milk?(R) Refuel Your School Contest 3Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 2Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 3
Straight Shafts with Serrated 5mm Platform with 0.2 tips; overall length 105mm In Titanium...
Straight Shafts with 0.12mm 1X2 Teeth With 5mm Tying Platform; In Titanium...
45 Degree Angle With 0.3, 12 Teeth with 5mm Tying Platform; In Titanium....
0.3mm tips; 9.5mm from tips to cross action; in Titanium....
Medicine Products: